Pindolol Augmentation in Patients With Treatment-Resistant Panic Disorder: A Double-Blind, Placebo-Controlled Trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The objective of this study was to determine the efficacy of pindolol as an augmentor of fluoxetine in treatment-resistant panic disorder (PD). Twenty-five outpatients having PD with or without agoraphobia were included. These patients had not responded to two different trials with antidepressants and an 8-week trial of fluoxetine 20 mg/day. Treatment-resistant PD was defined as a less than 20% reduction in score on the Panic Self-Questionnaire (number of attacks per week) (PSQ) and the Clinical Anxiety Scale With Panic Attacks (CAS+PA). These patients continued to receive fluoxetine 20 mg/day and were randomly assigned to additionally receive either pindolol (2.5 mg three times daily) or placebo for the following 4 weeks. Evaluations were performed weekly using the Hamilton Rating Scale for Anxiety, the Hamilton Rating Scale for Depression (HAM-D), the CAS+PA, the NIMH Anxiety Scale, the PSQ, and the Clinical Global Impression Scale. The data were analyzed using a repeated-measures analysis of variance (ANOVA) and a t-test for independent samples. Patients treated with the combination of pindolol and fluoxetine (N = 13) demonstrated a significant improvement over the patients treated with fluoxetine and placebo on all rating scales, with the exception of HAM-D. The statistical differences were shown using the repeated-measures ANOVA (baseline, week 2, week 4) and also with t-tests from the second week of the trial. These preliminary results demonstrate that pindolol has an augmenting effect on fluoxetine in patients with treatment-resistant PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most recent, comprehensive systematic review on pharmacological/non-pharmacological interventions in patients with TRPD, covering studies published from 1980 to the beginning of 2015 [9•], included 11 studies, only two of which were double-blind randomized controlled trials (RCTs) [16, 19].”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [16]
In the citing paper
“A small, preliminary RCT suggested that 4-week pindolol (7.5 mg/day) adjunctive treatment to fluoxetine (20 mg/day) was significantly superior to placebo in improving panic/anxiety symptoms in patients with PD who were resistant to at least two previous treatments with antidepressants and an 8-week trial with fluoxetine (20 mg/day) [16].”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [16]
In the citing paper
“Currently, there is no unequivocal definition of TRPD. Very heterogeneous criteria have been used across different studies, making interpretation of the results uncertain.”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [16]
Citations
Cites
Artigas, F. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030084009 · Cited by 510
Effectiveness of Pindolol With Selected Antidepressant Drugs in the Treatment of Major Depression
Blier, P., & Bergeron, R. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00011 · Cited by 317
Michelson, D., Lydiard, R. B., Pollack, M. H., Tamura, R. N., Hoog, S. L., Tepner, R., Demitrack, M. A., Tollefson, G. D., & the Fluoxetine Panic Disorder Study Group (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1570 · Cited by 123
Pindolol augmentation of antidepressant therapy
McAskill, R., Mir, S., & Taylor, D. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.3.203 · Cited by 81
Course and outcome in panic disorder: A review of recent follow‐up studies
Roy‐Byrne, P. P., & Cowley, D. S. (1994) · Anxiety · doi:10.1002/anxi.3070010402 · Cited by 78
Beta-blockers in anxiety disorders
Hayes, P. E., & Schulz, S. C. (1987) · Journal of Affective Disorders · doi:10.1016/0165-0327(87)90017-6 · Cited by 71
Course and outcome in panic disorder
Keller, M. B., & Hanks, D. L. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90005-d · Cited by 61
Blier, P., & Bergeron, R. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00005 · Cited by 57
Pharmacological Treatment of Panic Disorder
JUDD, F. K., NORMAN, T. R., & BURROWS, G. D. (1986) · International Clinical Psychopharmacology · doi:10.1097/00004850-198601000-00002 · Cited by 44
Bourin, M., Redrobe, J. P., & Baker, G. B. (1998) · Psychopharmacology · doi:10.1007/s002130050560 · Cited by 37
Research works printed but not linked: 1
- Walley, 1994, Am Fam Physician, 50, 1745
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“In a RCT, pindolol added to fluoxetine therapy in patients with treatment-resistant panic disorder was associated with significant improvement in panic disorder symptoms compared with fluoxetine plus placebo (Level 2) [286].”
BackgroundThe neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“A randomised placebo-controlled study found that pindolol augmentation of fluoxetine was superior to continued fluoxetine alone [I (PCT)] (Hirschmann et al., 2000).”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
“, 2002), and augmentation of fluoxetine with pindolol was superior to continued monotherapy with fluoxetine (Hirschmann et al., 2000).”
Background
Metadata
- Authors
- Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L.
- Affiliations
- Tel Aviv University (IL)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2000-10
- Volume
- 20
- Issue
- 5
- Pages
- 556-559
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2072437754
- Cited by
- 89
- References
- 11
- Citations by year
- 2025: 3 · 2024: 4 · 2021: 5 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 5 · 2014: 5 · 2013: 2 · 2012: 1
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- pindolol, agoraphobia, beta-blockers, antidepressant augmentation, panic attacks, anxiety symptoms
- MeSH terms
- Adrenergic beta-Antagonists, Adult, Analysis of Variance, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pindolol, Psychiatric Status Rating Scales, Anti-Anxiety Agents, Panic Disorder, Fluvoxamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pindolol Augmentation in Patients With Treatment-Resistant Panic Disorder: A Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1097/00004714-200010000-00011
- The paper
- Hirschmann, S., Dannon, P. N., Iancu, I., Dolberg, O. T., Zohar, J., & Grunhaus, L. (2000). Pindolol Augmentation in Patients With Treatment-Resistant Panic Disorder: A Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-200010000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.